SAGE Stock - Sage Therapeutics, Inc.
Unlock GoAI Insights for SAGE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.24M | $86.45M | $7.69M | $6.31M | $1.11B |
| Gross Profit | $31.80M | $84.30M | $6.87M | $5.75M | $1.11B |
| Gross Margin | 77.1% | 97.5% | 89.4% | 91.2% | 99.9% |
| Operating Income | $-432,370,000 | $-579,849,000 | $-546,989,000 | $-460,909,000 | $596.23M |
| Net Income | $-400,666,000 | $-541,489,000 | $-503,267,000 | $-450,827,000 | $606.07M |
| Net Margin | -971.5% | -626.3% | -6547.8% | -7146.9% | 54.4% |
| EPS | $-6.59 | $-9.05 | $-8.49 | $-7.68 | $11.66 |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 11th 2025 | BofA Securities | Resumed | Underperform | $5 |
| November 21st 2024 | RBC Capital Mkts | Upgrade | Sector Perform | $4 |
| October 10th 2024 | Raymond James | Resumed | Market Perform | - |
| October 4th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $10 |
| July 30th 2024 | TD Cowen | Downgrade | Hold | $10← $16 |
| July 25th 2024 | JP Morgan | Downgrade | Neutral | $12← $18 |
| May 29th 2024 | Robert W. Baird | Initiation | Neutral | $15 |
| May 29th 2024 | Citigroup | Initiation | Sell | $8 |
| April 17th 2024 | BofA Securities | Downgrade | Underperform | $14← $24 |
| December 12th 2023 | Deutsche Bank | Initiation | Hold | $21 |
| August 8th 2023 | Goldman | Downgrade | Neutral | $22 |
| August 8th 2023 | Needham | Downgrade | Hold | - |
| August 8th 2023 | Canaccord Genuity | Downgrade | Hold | $21← $64 |
| August 7th 2023 | BofA Securities | Downgrade | Neutral | $25← $66 |
| August 7th 2023 | Stifel | Downgrade | Hold | $22← $60 |
Earnings History & Surprises
SAGEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 30, 2025 | $-0.96 | $-0.79 | +17.7% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $-0.99 | $-1.01 | -2.0% | ✗ MISS |
Q1 2025 | Feb 11, 2025 | $-1.54 | $-1.56 | -1.3% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-1.52 | $-1.53 | -0.7% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-1.68 | $-1.70 | -1.2% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $-1.63 | $-1.80 | -10.4% | ✗ MISS |
Q1 2024 | Feb 14, 2024 | $-1.18 | $-0.55 | +53.4% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-2.64 | $-2.81 | -6.4% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-2.53 | $-2.68 | -5.9% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-2.50 | $-2.46 | +1.6% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $-2.37 | $-2.47 | -4.2% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-2.16 | $-2.31 | -6.9% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-2.16 | $-2.13 | +1.4% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-2.09 | $-2.07 | +1.0% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-2.16 | $-2.12 | +1.9% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-1.84 | $-2.21 | -20.1% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-1.69 | $-1.83 | -8.3% | ✗ MISS |
Q2 2021 | May 4, 2021 | $-1.98 | $-1.64 | +17.2% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $-2.17 | $-2.47 | -13.8% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-2.30 | $-2.03 | +11.7% | ✓ BEAT |
Frequently Asked Questions about SAGE
What is SAGE's current stock price?
What is the analyst price target for SAGE?
What sector is Sage Therapeutics, Inc. in?
What is SAGE's market cap?
Does SAGE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SAGE for comparison